Key Market Indicators
Sales of antirheumatic medicines in Finland are forecast to reach $51 million by 2026, a decrease of 0.8% over five years. The Finnish market had already dropped 0.6% each year since 2003. Norway overtook Finland in 2021, with sales of $55 million, followed by Germany, Spain and Canada.
